Advertisement
News
Subscribe to MDT Magazine News

DNA of 50 Breast Cancer Patients Decoded

April 2, 2011 6:33 am | by AACR | Comments

Tweet • Reveals complexity and hints toward personalized medicine. • Patient tumors had more than 1,700 mutations. • Abstract to be presented during an AACR press conference. ORLANDO, Fla. - In one of the largest cancer genomics investigations reported to date, scientists have sequenced...

TOPICS:

Target for Lung Cancer Chemoprevention Identified

April 2, 2011 6:33 am | by AACR | Comments

Tweet • Endobronchial dysplasia can be modified pharmacologically. • Effect on endobronchial dysplasia was seen in former smokers. • Full study details to be presented at AACR press conference. ORLANDO, Fla. - Scientists have identified a biomarker for measuring the success of lung cancer...

TOPICS:

Combining MEK and PI3K Inhibitors Appears Encouraging in a Safety Study with Early Signs of Anti-tumor Activity

April 2, 2011 6:33 am | by AACR | Comments

Tweet • Combination therapy targets MEK and PI3K pathways. • Phase I trials of single agent MEK and PI3K pathway inhibitors alone have shown signs of anti-tumor activity. • Abstract to be presented at AACR press conference. ORLANDO, Fla. - The combination of two compounds that inhibit two...

TOPICS:
Advertisement

BATTLE Researchers Identify New Biomarkers for EGFR Inhibition

April 2, 2011 6:33 am | by AACR | Comments

Tweet • Protocol was one of the first to treat patients based on molecular profiling. • Two gene signatures were predictive of efficacy for erlotinib. • Updated results to be presented during AACR press conference. ORLANDO, Fla. - Scientists are continuing their work on the...

TOPICS:

New Inhibitor Prevented Lesions, Reduced Tumor Size in Basal Cell Cancer

April 2, 2011 6:32 am | by AACR | Comments

Tweet • Tumors decreased by 24 cm in patients who received GDC-0449. • No patients receiving GDC-0449 required surgery to remove tumors. • Data safety monitoring board stopped placebo arm at interim analysis. ORLANDO, Fla. - A new hedgehog pathway inhibitor demonstrated efficacy in...

TOPICS:

Data suggest liver experts should take care when prescribing novel antiviral HCV drugs

April 2, 2011 12:37 am | by EurekAlert | Comments

(European Association for the Study of the Liver) Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus must be prescribed and monitored by experts and specialists to ensure resistance is minimized.

TOPICS:

New data show non-alcoholic fatty liver disease will reach epidemic status in the US

April 1, 2011 11:36 pm | by EurekAlert | Comments

(European Association for the Study of the Liver) According to new data presented today at the International Liver Congress, the United States could soon be faced with an epidemic of non-alcoholic fatty liver disease, one of the major contributing factors of chronic liver disease,...

TOPICS:

Thalidomide shows efficacy as adjuvant therapy for hepatocellular carcinoma patients

April 1, 2011 11:35 pm | by EurekAlert | Comments

(European Association for the Study of the Liver) Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma, according to data presented at the International Liver Congress 2011.

TOPICS:
Advertisement

Medmira posts $1.3-million Q2 loss as sales plunge below $200,000

April 1, 2011 4:45 pm | by The Associated Press | Comments

MedMira Inc. (TSXV:MIR) posted a $1.3-million loss in the second quarter as revenue dropped by 63 per cent compared with the year-earlier results, the developer of rapid medical diagnostics said Friday.The Halifax-based company said its revenue fell to $188,793 in the three months ended Jan....

FDA Expanding MedSun Program To Better Track Adverse Events

April 1, 2011 2:40 pm | by U.S. Food & Drug Administration | Comments

BALTIMORE — The FDA is expanding its medical product surveillance network (MedSun) to better track adverse events, a move that comes shortly after the Office of Inspector General (OIG) said CDRH has failed to act on several recommendations for adverse event followup.

ReBuilder Gets Warning for Lack of Supplier, Complaint Documentation

April 1, 2011 2:38 pm | by U.S. Food & Drug Administration | Comments

ReBuilder Medical has been warned after an FDA inspection found no documentation of supplier qualification, despite a company requirement to test vendors’ product samples before approval.

New Tool Allows for an Alternate Method of Prostate Cancer Diagnosis

April 1, 2011 1:32 pm | by AACR | Comments

Tweet   • Test conducted in the non-cancerous part of the prostate. • May aid in localization of cancer lesion within the prostate gland. PHILADELPHIA - Researchers have found that it may not be necessary to look for tumors directly in patients with prostate cancer - analyzing...

TOPICS:

RSB Spine, LLC, Announces Record First-Quarter 2011 Revenue

April 1, 2011 12:36 pm | by Bio-Medicine.Org | Comments

CLEVELAND, April 1, 2011 /- RSB Spine, LLC, a medical device company focused on developing unique modular fusion products for surgical treatment of degenerative disc disease, today announced a 145% sales increase for the first quarter of 2011 versus first-quarter 2010, marking its sixth...

TOPICS:

Plato BioPharma, Inc. Sponsors Novel Disease Model Award

April 1, 2011 12:33 pm | by Bio-Medicine.Org | Comments

WESTMINSTER, Colo., April 1, 2011 /- Plato BioPharma, Inc. ("PBI") announced today that the company has committed to sponsor The American Physiological Society's (APS) Novel Disease Model Awards for 2011 through 2013.  Each year, the APS's Physiologists in Industry Committee selects...

TOPICS:

Tenn., Ky. turn over lethal injection drug to DEA

April 1, 2011 11:45 am | by KRISTIN M. HALL - Associated Press - Associated Press | Comments

Kentucky and Tennessee became the second and third states on Friday to turn over their supplies of a key lethal injection drug to the U.S. Drug Enforcement Administration, which is investigating concerns about how the drug was imported during a national shortage.Several states scrambled to find...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading